Table 2.
Clinicopathological characteristics according to HER2 protein expression intensity.
| Total (n = 680) | Negative (n = 462) | Borderline (n = 182) | Positive (n = 36) | p-value | |
|---|---|---|---|---|---|
| Age | <0.001 | ||||
| <60 | 340 (50.0%) | 252 (54.5%) | 76 (41.8%) | 12 (33.3%) | |
| ≥60 | 340 (50.0%) | 210 (45.5%) | 106 (58.2%) | 24 (66.7%) | |
| Sex | 0.002 | ||||
| M | 456 (67.1%) | 291 (63.0%) | 138 (75.8%) | 27 (75.0%) | |
| F | 224 (32.9%) | 171 (37.0%) | 44 (24.2%) | 9 (25.0%) | |
| Tumour size | 0.027 | ||||
| ≤20 | 176 (25.9%) | 132 (28.6%) | 37 (20.3%) | 7 (19.4%) | |
| >20 | 504 (74.1%) | 330 (71.4%) | 145 (79.7%) | 29 (80.6%) | |
| Vertical location | 0.928 | ||||
| UT/MT | 381 (56.0%) | 259 (56.1%) | 101 (55.5%) | 21 (58.3%) | |
| LT | 299 (44.0%) | 203 (43.9%) | 81 (44.5%) | 15 (41.7%) | |
| Gross appearance | 0.065 | ||||
| E | 109 (16.0%) | 68 (14.7%) | 31 (17.0%) | 10 (27.8%) | |
| FD | 571 (84.0%) | 394 (85.3%) | 151 (83.0%) | 26 (72.2%) | |
| Depth of invasion | <0.001 | ||||
| M | 343 (50.4%) | 259 (56.1%) | 70 (38.5%) | 14 (38.9%) | |
| SM | 337 (49.6%) | 203 (43.9%) | 112 (61.5%) | 22 (61.1%) | |
| Histology | <0.001 | ||||
| Differentiated | 316 (46.5%) | 177 (38.3%) | 110 (60.4%) | 29 (80.6%) | |
| Undifferentiated | 364 (53.5%) | 285 (61.7%) | 72 (39.6%) | 7 (19.4%) | |
| LVI | 0.017 | ||||
| No | 540 (79.4%) | 377 (81.6%) | 139 (76.4%) | 24 (66.7%) | |
| Yes | 140 (20.6%) | 85 (18.4%) | 43 (23.6%) | 12 (33.3%) | |
| Node metastasis | 0.296 | ||||
| No | 600 (88.2%) | 410 (88.7%) | 161 (88.5%) | 29 (80.6%) | |
| Yes | 80 (11.8%) | 52 (11.3%) | 21 (11.5%) | 7 (19.4%) |
EGC, early gastric cancer; SMEGC, synchronous multiple EGC; UT, upper third; MT, mid third; LT, low third; AW, anterior wall; GC, great curvature; PW, posterior wall; LC, lesser curvature; LVI, lymphovascular invasion; VL, vertical location; HL, horizontal location.